Loading…
Acute loss of vision during therapy of chronic hepatitis C
A patient undergoing combined therapy of chronic hepatitis C with pegylated interferon-α-2a (PEG-IFN-α-2a) and ribavirin suddenly developed severe loss of visual acuity. A central vein occlusion with macular edema was found and intravitreal injections of bevacizumab were initiated. Retinal occlusion...
Saved in:
| Published in: | Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2011-06, Vol.108 (6), p.561 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | ger |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | |
| container_issue | 6 |
| container_start_page | 561 |
| container_title | Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft |
| container_volume | 108 |
| creator | Salgado, J P Khoramnia, R Maier, M M Lohmann, C P Winkler von Mohrenfels, C |
| description | A patient undergoing combined therapy of chronic hepatitis C with pegylated interferon-α-2a (PEG-IFN-α-2a) and ribavirin suddenly developed severe loss of visual acuity. A central vein occlusion with macular edema was found and intravitreal injections of bevacizumab were initiated. Retinal occlusion is a known complication of therapy with pegylated interferon-α-2a and ribavirin. An interdisciplinary assessment of patients treated for a chronic hepatitis C as well as an early anti-VEGF administration can be helpful in the therapy of this complication of chronic hepatitis C. |
| doi_str_mv | 10.1007/s00347-010-2327-0 |
| format | article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_21271253</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21271253</sourcerecordid><originalsourceid>FETCH-LOGICAL-p108t-581700c646382d099fa31acdd1d77700db6eb6d6c8b1aa5f62b03b001f0fcf403</originalsourceid><addsrcrecordid>eNo1j81Kw0AURgdBbK0-gBuZFxi9d24yk7orQatQcNOuy_yakTYJmUTo21tRV-eDAx8cxu4QHhBAP2YAKrQABCFJnscFm2NBJKCQNGPXOX8CgCpJXrGZRKlRljRnTys3jYEfupx5F_lXyqlruZ-G1H7wsQmD6U8_wjVD1ybHm9CbMY0p8_qGXUZzyOH2jwu2e3ne1q9i875-q1cb0SNUoygr1ABOFYoq6WG5jIbQOO_Ra3023qpglVeusmhMGZW0QBYAI0QXC6AFu__97Sd7DH7fD-lohtP-P4K-ASx3Rr4</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Acute loss of vision during therapy of chronic hepatitis C</title><source>Alma/SFX Local Collection</source><creator>Salgado, J P ; Khoramnia, R ; Maier, M M ; Lohmann, C P ; Winkler von Mohrenfels, C</creator><creatorcontrib>Salgado, J P ; Khoramnia, R ; Maier, M M ; Lohmann, C P ; Winkler von Mohrenfels, C</creatorcontrib><description>A patient undergoing combined therapy of chronic hepatitis C with pegylated interferon-α-2a (PEG-IFN-α-2a) and ribavirin suddenly developed severe loss of visual acuity. A central vein occlusion with macular edema was found and intravitreal injections of bevacizumab were initiated. Retinal occlusion is a known complication of therapy with pegylated interferon-α-2a and ribavirin. An interdisciplinary assessment of patients treated for a chronic hepatitis C as well as an early anti-VEGF administration can be helpful in the therapy of this complication of chronic hepatitis C.</description><identifier>EISSN: 1433-0423</identifier><identifier>DOI: 10.1007/s00347-010-2327-0</identifier><identifier>PMID: 21271253</identifier><language>ger</language><publisher>Germany</publisher><subject>Adult ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; Bevacizumab ; Drug Therapy, Combination ; Fluorescein Angiography ; Hepatitis C, Chronic - drug therapy ; Humans ; Image Processing, Computer-Assisted ; Imaging, Three-Dimensional ; Interferon-alpha - adverse effects ; Interferon-alpha - therapeutic use ; Intravitreal Injections ; Macular Edema - chemically induced ; Macular Edema - drug therapy ; Male ; Polyethylene Glycols - adverse effects ; Polyethylene Glycols - therapeutic use ; Recombinant Proteins - adverse effects ; Recombinant Proteins - therapeutic use ; Retinal Vein Occlusion - chemically induced ; Retinal Vein Occlusion - drug therapy ; Ribavirin - adverse effects ; Ribavirin - therapeutic use ; Tomography, Optical Coherence ; Vision, Low - chemically induced ; Vision, Low - diagnosis ; Visual Acuity - drug effects</subject><ispartof>Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2011-06, Vol.108 (6), p.561</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21271253$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Salgado, J P</creatorcontrib><creatorcontrib>Khoramnia, R</creatorcontrib><creatorcontrib>Maier, M M</creatorcontrib><creatorcontrib>Lohmann, C P</creatorcontrib><creatorcontrib>Winkler von Mohrenfels, C</creatorcontrib><title>Acute loss of vision during therapy of chronic hepatitis C</title><title>Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft</title><addtitle>Ophthalmologe</addtitle><description>A patient undergoing combined therapy of chronic hepatitis C with pegylated interferon-α-2a (PEG-IFN-α-2a) and ribavirin suddenly developed severe loss of visual acuity. A central vein occlusion with macular edema was found and intravitreal injections of bevacizumab were initiated. Retinal occlusion is a known complication of therapy with pegylated interferon-α-2a and ribavirin. An interdisciplinary assessment of patients treated for a chronic hepatitis C as well as an early anti-VEGF administration can be helpful in the therapy of this complication of chronic hepatitis C.</description><subject>Adult</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Bevacizumab</subject><subject>Drug Therapy, Combination</subject><subject>Fluorescein Angiography</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Humans</subject><subject>Image Processing, Computer-Assisted</subject><subject>Imaging, Three-Dimensional</subject><subject>Interferon-alpha - adverse effects</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Intravitreal Injections</subject><subject>Macular Edema - chemically induced</subject><subject>Macular Edema - drug therapy</subject><subject>Male</subject><subject>Polyethylene Glycols - adverse effects</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Recombinant Proteins - adverse effects</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Retinal Vein Occlusion - chemically induced</subject><subject>Retinal Vein Occlusion - drug therapy</subject><subject>Ribavirin - adverse effects</subject><subject>Ribavirin - therapeutic use</subject><subject>Tomography, Optical Coherence</subject><subject>Vision, Low - chemically induced</subject><subject>Vision, Low - diagnosis</subject><subject>Visual Acuity - drug effects</subject><issn>1433-0423</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNo1j81Kw0AURgdBbK0-gBuZFxi9d24yk7orQatQcNOuy_yakTYJmUTo21tRV-eDAx8cxu4QHhBAP2YAKrQABCFJnscFm2NBJKCQNGPXOX8CgCpJXrGZRKlRljRnTys3jYEfupx5F_lXyqlruZ-G1H7wsQmD6U8_wjVD1ybHm9CbMY0p8_qGXUZzyOH2jwu2e3ne1q9i875-q1cb0SNUoygr1ABOFYoq6WG5jIbQOO_Ra3023qpglVeusmhMGZW0QBYAI0QXC6AFu__97Sd7DH7fD-lohtP-P4K-ASx3Rr4</recordid><startdate>201106</startdate><enddate>201106</enddate><creator>Salgado, J P</creator><creator>Khoramnia, R</creator><creator>Maier, M M</creator><creator>Lohmann, C P</creator><creator>Winkler von Mohrenfels, C</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>201106</creationdate><title>Acute loss of vision during therapy of chronic hepatitis C</title><author>Salgado, J P ; Khoramnia, R ; Maier, M M ; Lohmann, C P ; Winkler von Mohrenfels, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p108t-581700c646382d099fa31acdd1d77700db6eb6d6c8b1aa5f62b03b001f0fcf403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>ger</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Bevacizumab</topic><topic>Drug Therapy, Combination</topic><topic>Fluorescein Angiography</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Humans</topic><topic>Image Processing, Computer-Assisted</topic><topic>Imaging, Three-Dimensional</topic><topic>Interferon-alpha - adverse effects</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Intravitreal Injections</topic><topic>Macular Edema - chemically induced</topic><topic>Macular Edema - drug therapy</topic><topic>Male</topic><topic>Polyethylene Glycols - adverse effects</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Recombinant Proteins - adverse effects</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Retinal Vein Occlusion - chemically induced</topic><topic>Retinal Vein Occlusion - drug therapy</topic><topic>Ribavirin - adverse effects</topic><topic>Ribavirin - therapeutic use</topic><topic>Tomography, Optical Coherence</topic><topic>Vision, Low - chemically induced</topic><topic>Vision, Low - diagnosis</topic><topic>Visual Acuity - drug effects</topic><toplevel>online_resources</toplevel><creatorcontrib>Salgado, J P</creatorcontrib><creatorcontrib>Khoramnia, R</creatorcontrib><creatorcontrib>Maier, M M</creatorcontrib><creatorcontrib>Lohmann, C P</creatorcontrib><creatorcontrib>Winkler von Mohrenfels, C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salgado, J P</au><au>Khoramnia, R</au><au>Maier, M M</au><au>Lohmann, C P</au><au>Winkler von Mohrenfels, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acute loss of vision during therapy of chronic hepatitis C</atitle><jtitle>Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft</jtitle><addtitle>Ophthalmologe</addtitle><date>2011-06</date><risdate>2011</risdate><volume>108</volume><issue>6</issue><spage>561</spage><pages>561-</pages><eissn>1433-0423</eissn><abstract>A patient undergoing combined therapy of chronic hepatitis C with pegylated interferon-α-2a (PEG-IFN-α-2a) and ribavirin suddenly developed severe loss of visual acuity. A central vein occlusion with macular edema was found and intravitreal injections of bevacizumab were initiated. Retinal occlusion is a known complication of therapy with pegylated interferon-α-2a and ribavirin. An interdisciplinary assessment of patients treated for a chronic hepatitis C as well as an early anti-VEGF administration can be helpful in the therapy of this complication of chronic hepatitis C.</abstract><cop>Germany</cop><pmid>21271253</pmid><doi>10.1007/s00347-010-2327-0</doi></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1433-0423 |
| ispartof | Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2011-06, Vol.108 (6), p.561 |
| issn | 1433-0423 |
| language | ger |
| recordid | cdi_pubmed_primary_21271253 |
| source | Alma/SFX Local Collection |
| subjects | Adult Antibodies, Monoclonal, Humanized - therapeutic use Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Bevacizumab Drug Therapy, Combination Fluorescein Angiography Hepatitis C, Chronic - drug therapy Humans Image Processing, Computer-Assisted Imaging, Three-Dimensional Interferon-alpha - adverse effects Interferon-alpha - therapeutic use Intravitreal Injections Macular Edema - chemically induced Macular Edema - drug therapy Male Polyethylene Glycols - adverse effects Polyethylene Glycols - therapeutic use Recombinant Proteins - adverse effects Recombinant Proteins - therapeutic use Retinal Vein Occlusion - chemically induced Retinal Vein Occlusion - drug therapy Ribavirin - adverse effects Ribavirin - therapeutic use Tomography, Optical Coherence Vision, Low - chemically induced Vision, Low - diagnosis Visual Acuity - drug effects |
| title | Acute loss of vision during therapy of chronic hepatitis C |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T18%3A27%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acute%20loss%20of%20vision%20during%20therapy%20of%20chronic%20hepatitis%20C&rft.jtitle=Der%20Ophthalmologe%20:%20Zeitschrift%20der%20Deutschen%20Ophthalmologischen%20Gesellschaft&rft.au=Salgado,%20J%20P&rft.date=2011-06&rft.volume=108&rft.issue=6&rft.spage=561&rft.pages=561-&rft.eissn=1433-0423&rft_id=info:doi/10.1007/s00347-010-2327-0&rft_dat=%3Cpubmed%3E21271253%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p108t-581700c646382d099fa31acdd1d77700db6eb6d6c8b1aa5f62b03b001f0fcf403%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/21271253&rfr_iscdi=true |